Medicenna Therapeutics Co... (MDNA)
Medicenna Therapeutics Statistics
Share Statistics
Medicenna Therapeutics has 0 shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 0 |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 48.76M |
| Failed to Deliver (FTD) Shares | 6.8K |
| FTD / Avg. Volume | 0.54% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 35.63 and the forward PE ratio is null. Medicenna Therapeutics's PEG ratio is -0.34.
| PE Ratio | 35.63 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 1.87 |
| P/FCF Ratio | -4.35 |
| PEG Ratio | -0.34 |
Enterprise Valuation
Medicenna Therapeutics has an Enterprise Value (EV) of 21.52M.
| EV / Sales | 0 |
| EV / EBITDA | -1.32 |
| EV / EBIT | -1.7 |
| EV / FCF | -1.7 |
Financial Position
The company has a current ratio of 9.57, with a Debt / Equity ratio of 0.
| Current Ratio | 9.57 |
| Quick Ratio | 9.57 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 5.25% and Return on Invested Capital is 7.69%.
| Return on Equity | 5.25% |
| Return on Assets | 4.24% |
| Return on Invested Capital | 7.69% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $96.69K |
| Employee Count | 16 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -11.6M |
| Effective Tax Rate | 115.4% |
Stock Price Statistics
The stock price has increased by -56.16% in the last 52 weeks. The beta is 0.77, so Medicenna Therapeutics's price volatility has been higher than the market average.
| Beta | 0.77 |
| 52-Week Price Change | -56.16% |
| 50-Day Moving Average | 0.29 |
| 200-Day Moving Average | 0.48 |
| Relative Strength Index (RSI) | 33.89 |
| Average Volume (20 Days) | 1.26M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -16.3M |
| Net Income | 1.55M |
| EBITDA | -16.3M |
| EBIT | -21.64M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
The company has 33.6M in cash and 0 in debt, giving a net cash position of 33.6M.
| Cash & Cash Equivalents | 33.6M |
| Total Debt | 0 |
| Net Cash | 33.6M |
| Retained Earnings | -80.98M |
| Total Assets | 27.74M |
| Working Capital | 23.99M |
Cash Flow
In the last 12 months, operating cash flow was -12.66M and capital expenditures 0, giving a free cash flow of -12.66M.
| Operating Cash Flow | -12.66M |
| Capital Expenditures | 0 |
| Free Cash Flow | -12.66M |
| FCF Per Share | -0.2 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MDNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 2.81% |
| FCF Yield | -22.96% |
Analyst Forecast
The average price target for MDNA is $2.5, which is 1462.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.5 |
| Price Target Difference | 1462.5% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -4.13 |
| Piotroski F-Score | 1 |